Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Piperidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.46 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.90 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL27684596 | 1.00 | ALDH1A1 (0.90) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Piperidine SCHEMBL7575332 | 1.00 | — | — | |
| Azepane SCHEMBL20563677 | 1.00 | — | — | |
| Water SCHEMBL27684593 | 1.00 | ALDH1A1 (0.90) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Piperidine SCHEMBL4616564 | 1.00 | — | — | |
| Piperidine SCHEMBL7575329 | 1.00 | ALDH1A1 (0.90) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Piperidine SCHEMBL28700802 | 1.00 | ALDH1A1 (0.90) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT | |
| Azepane SCHEMBL29258022 | 0.95 | — | — | |
| Piperidine SCHEMBL9028300 | 0.95 | — | — | |
| Piperidine SCHEMBL30996101 | 0.95 | ALDH1A1 (0.82) | ALDH1A1CXCR4SMN1; SMN2HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023139322-A1 | HYDROSILYLATION PROCESS PHOTOCATALYSED BY A MANGANESE COMPLEX | ELKEM SILICONES FRANCE SAS (FR) | 2023-07-27 | — | — | WO | claimed |
| EP-2935286-B1 | HYDROSILYLATION METHOD | ELKEM SILICONES FRANCE SAS (FR) | 2018-08-01 | — | — | EP | claimed |
| EP-0886520-A1 | CAFFEINE AND CLEMASTINE FOR TREATING RESPIRATORY DISORDERS | THE PROCTER & GAMBLE COMPANY (US) | 1998-12-30 | — | — | EP | claimed |
| EP-0841947-A1 | COMPOSITIONS CONTAINING ANALGESICS AND ANTIHISTAMINES AND METHODS FOR TREATING RESPIRATORY DISORDERS | THE PROCTER & GAMBLE COMPANY (US) | 1998-05-20 | — | — | EP | claimed |
| WO-1997032586-A1 | CAFFEINE AND CLEMASTINE FOR TREATING RESPIRATORY DISORDERS | THE PROCTER & GAMBLE COMPANY (US) | 1997-09-12 | — | — | WO | claimed |
| US-5648358-A | CAFFEINE AND PYRROLIDINE OR PIPERIDINE ETHER ANTIHISTAMINE | PROCTER & GAMBLE COMPANY, THE | 1997-07-15 | — | — | US | claimed |
| WO-1997004808-A1 | COMPOSITIONS CONTAINING ANALGESICS AND ANTIHISTAMINES AND METHODS FOR TREATING RESPIRATORY DISORDERS | THE PROCTER & GAMBLE COMPANY (US) | 1997-02-13 | — | — | WO | claimed |
| JP-4356462-A | — | — | None | — | — | JP | disclosed |
| WO-2024146993-A1 | HYDROSILYLATION PROCESS CATALYSED BY A MANGANESE COMPLEX | ELKEM SILICONES FRANCE SAS (FR) | 2024-07-11 | — | — | WO | disclosed |
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-04-23 | — | — | US | disclosed |
| CN-111936231-B | Nanoparticles of zero-valent metal CO complexes useful as hydrosilylation and dehydrogenative silylation catalysts | 埃肯有机硅法国有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20230264183-A1 | NANOPARTICLES OF CO COMPLEXES OF ZERO-VALENT METALS THAT CAN BE USED AS HYDROSILYLATION AND DEHYDROGENATIVE SILYLATION CATALYSTS | ELKEM SILICONES FRANCE SAS (FR) | 2023-08-24 | — | — | US | disclosed |
| WO-2023139322-A1 | HYDROSILYLATION PROCESS PHOTOCATALYSED BY A MANGANESE COMPLEX | ELKEM SILICONES FRANCE SAS (FR) | 2023-07-27 | — | — | WO | disclosed |
| US-5169855-A | PIPERIDINE ETHER DERIVATIVES AS PSYCHOTROPIC DRUGS OR PLANT FUNGICIDES | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-12-08 | — | — | US | disclosed |
| US-5169855-A | PIPERIDINE ETHER DERIVATIVES AS PSYCHOTROPIC DRUGS OR PLANT FUNGICIDES | DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-12-08 | — | — | US | disclosed |
| CN-1058399-A | New piperidine ether and thioether as cholesteral biosynthesis inhibitor | MERRELL DOW PHARMA (US) | 1992-02-05 | — | — | CN | disclosed |
| CN-1058399-A | New piperidine ether and thioether as cholesteral biosynthesis inhibitor | MERRELL DOW PHARMA (US) | 1992-02-05 | — | — | CN | disclosed |
| EP-0449187-A2 | Piperidin ether derivatives as psychotropic drugs or plant fungicides | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-10-02 | — | — | EP | disclosed |
| EP-0449187-A2 | Piperidin ether derivatives as psychotropic drugs or plant fungicides | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-10-02 | — | — | EP | disclosed |
| US-3862158-A | PIPERIDINE ETHERS | HOFFMANN LA ROCHE | 1975-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964973-B2 | Substituted bicyclic compounds useful as T cell activators | DGKA, DGKZ, DGKK | PDE4A 1415/4885KDR 2426/4885ALDH1A1 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.